Academic Journal
Utilization of Similar Epitopes to Develop Viral Vaccines that Produce Lifelong Immunity.
| Τίτλος: | Utilization of Similar Epitopes to Develop Viral Vaccines that Produce Lifelong Immunity. |
|---|---|
| Συγγραφείς: | Yang XY; College of Resources, Sichuan Agricultural University, Chengdu, China., Fu YF; College of Resources, Sichuan Agricultural University, Chengdu, China., Xie LB; College of Resources, Sichuan Agricultural University, Chengdu, China., Zhang ZW; College of Resources, Sichuan Agricultural University, Chengdu, China., Yuan S; College of Resources, Sichuan Agricultural University, Chengdu, China. |
| Πηγή: | Viral immunology [Viral Immunol] 2026 Oct; Vol. 39 (8), pp. 313-317. Date of Electronic Publication: 2026 Jul 30. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 8801552 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-8976 (Electronic) Linking ISSN: 08828245 NLM ISO Abbreviation: Viral Immunol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: New York, NY : Mary Ann Liebert, Inc., c1987- |
| Ιατρικοί όροι (MeSH): | SARS-CoV-2*/immunology , Spike Glycoprotein, Coronavirus*/immunology , Spike Glycoprotein, Coronavirus*/genetics , COVID-19 Vaccines*/immunology , Epitopes*/immunology , Viral Vaccines*/immunology , COVID-19*/prevention & control , COVID-19*/immunology , Immunologic Memory*, Antibodies, Viral/immunology ; Antibodies, Viral/blood ; Antibodies, Neutralizing/immunology ; Animals ; Humans ; Rabbits ; Half-Life ; Vaccine Development |
| Περίληψη: | The half-life (HL) of specific antibodies produced by the human body against various viruses varies from about 4 months to 11,000 years. Due to their short half-lives, multiple-dose vaccinations and annual revaccination are usually required for most viruses, which cause a large economic burden, especially in developing countries with limited storage of vaccines. Protein assemblies with a high degree of repetitiveness and organization are known to induce strong and long-lasting immune responses. However, the detailed quantitative law is still unknown. Through epitope analysis of representative viruses, we found that the longevity of immunological memory may be correlated with the number of epitopes with similar sequences (EWSS). Accordingly, a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with 4.5-times higher antibody titers and over 100 months of HL was developed in a rabbit model. The decay pattern of antibodies against each epitope or the entire SARS-CoV-2 spike protein was roughly correlated with the number of EWSS in immunization treatments, that is, for every additional EWSS, the HL of the antibody would be doubled. This study also discusses improvement measures for vaccines against other viruses. |
| Competing Interests: | Author Disclosure StatementThe authors declare that they have no competing interests. |
| Contributed Indexing: | Keywords: SARS-CoV-2; antibody’s half-life; duration of immunity; epitopes with similar sequences |
| Substance Nomenclature: | 0 (Antibodies, Viral) 0 (Spike Glycoprotein, Coronavirus) 0 (COVID-19 Vaccines) 0 (Epitopes) 0 (spike protein, SARS-CoV-2) 0 (Viral Vaccines) 0 (Antibodies, Neutralizing) |
| Entry Date(s): | Date Created: 20260730 Date Completed: 20260811 Latest Revision: 20260811 |
| Update Code: | 20260811 |
| DOI: | 10.1177/08828245261474283 |
| PMID: | 42529933 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1557-8976 |
|---|---|
| DOI: | 10.1177/08828245261474283 |